Use of telephone and web interfaces of interactive response technology at clinical investigator sites in clinical trials

被引:0
|
作者
Saarela, Anna-Leena [1 ,2 ]
Walzer, Anja [3 ]
Juppo, Anne Mari [1 ]
机构
[1] Univ Helsinki, Div Pharmaceut Chem & Technol, Fac Pharm, Formulat & Ind Pharm Unit, Helsinki, Finland
[2] Crown CRO Oy, Vaisalantie 4, Espoo 02130, Finland
[3] Bayer AG, Dev, Pharmaceut, Berlin, Germany
关键词
Clinical trials; interactive response technology; interactive voice response; interactive web response; user interface; randomization; SYSTEMS;
D O I
10.1177/1740774519832329
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Interactive response technologies are used in clinical trials to provide services such as automated randomization and medication logistics management. The objective of this article is to investigate the usage of telephone (Interactive Voice Response) and web (Interactive Web Response) interfaces of interactive response technologies at clinical investigator sites in clinical trials, to obtain information about the preferences of interactive response technology end users between the telephone and web interfaces, and to explore the relevance of the telephone interface in this setting. Methods The data consist of an online survey conducted in spring 2016 with clinical investigators, study nurses, and pharmacists in 13 countries. Results Ninety-eight percent of survey respondents preferred the web interface over the telephone interface, the most important reason being superior usability. However, the respondents indicated the usability of interactive response technology interfaces is not optimal, and lack of integration and consistency across systems is common. A vast majority of interactive response technology end users at clinical sites prefer to use the web interface over the telephone interface, but most also feel there would need to be a back-up system. Conclusions Based on the results, it would be beneficial to improve the usability of the interactive response technology interfaces, and to increase consistency across systems from the current level. Support to and training of the users, as well as clarifying the responsibilities between sites and the sponsor should also be a focal point. Study sponsors should explore with interactive response technology service providers how removing the telephone interface would impact future studies, and whether there could be a more efficient means to achieve a reliable back-up to the web interface instead of a dedicated telephone interface.
引用
收藏
页码:297 / 305
页数:9
相关论文
共 50 条
  • [21] Investigator experiences with financial conflicts of interest in clinical trials
    Paula A Rochon
    Melanie Sekeres
    John Hoey
    Joel Lexchin
    Lorraine E Ferris
    David Moher
    Wei Wu
    Sunila R Kalkar
    Marleen Van Laethem
    Andrea Gruneir
    Jennifer Gold
    James Maskalyk
    David L Streiner
    Nathan Taback
    An-Wen Chan
    [J]. Trials, 12
  • [22] THE INVESTIGATOR-SPONSORED IND IN CLINICAL-TRIALS
    HAAKENSON, C
    FYE, CL
    SATHER, MR
    TOUSSAINT, DJ
    [J]. CONTROLLED CLINICAL TRIALS, 1987, 8 (02): : 101 - 109
  • [23] Investigator experiences with financial conflicts of interest in clinical trials
    Rochon, Paula A.
    Sekeres, Melanie
    Hoey, John
    Lexchin, Joel
    Ferris, Lorraine E.
    Moher, David
    Wu, Wei
    Kalkar, Sunila R.
    Van Laethem, Marleen
    Gruneir, Andrea
    Gold, Jennifer
    Maskalyk, James
    Streiner, David L.
    Taback, Nathan
    Chan, An-Wen
    [J]. TRIALS, 2011, 12
  • [24] ECG subanalyses in clinical trials: An investigator's perspective
    Sgarbossa, EB
    Pinski, SL
    Barbagelata, A
    Goodman, SG
    Natale, A
    Gates, KB
    Wagner, GS
    [J]. JOURNAL OF ELECTROCARDIOLOGY, 1999, 32 : 114 - 121
  • [25] GUIDELINES FOR CLINICAL INVESTIGATOR INVOLVEMENT IN INDUSTRY-SPONSORED CLINICAL-TRIALS
    PANACEK, EA
    LEWIS, RJ
    [J]. ACADEMIC EMERGENCY MEDICINE, 1995, 2 (01) : 43 - 45
  • [26] Improving the efficiency of clinical trials by standardizing processes for Investigator Initiated Trials
    Mudaranthakam, Dinesh Pal
    Phadnis, Milind A.
    Krebill, Ron
    Clark, Lauren
    Wick, Jo A.
    Thompson, Jeffrey
    Keighley, John
    Gajewski, Byron J.
    Koestler, Devin C.
    Mayo, Matthew S.
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 18
  • [27] Transparency and accuracy in funding investigator-initiated clinical trials: a systematic search in clinical trials databases
    Madeira, Catarina
    Santos, Francisco
    Kubiak, Christine
    Demotes, Jacques
    Monteiro, Emilia Carreira
    [J]. BMJ OPEN, 2019, 9 (05):
  • [28] USE OF INTERACTIVE COMPUTER-TECHNOLOGY IN OPEN CLINICAL-TRIALS - STUDY WITH TRAZODONE IN DEPRESSED-PATIENTS
    BENKELFAT, C
    GAY, C
    RENARDET, M
    [J]. NEUROPSYCHOBIOLOGY, 1986, 15 : 10 - 14
  • [29] Certification of Clinical Sites in Good Clinical Practices for the Conduct of Clinical Trials
    Cuevas Perez, Olga Lidia
    Fernandez Ruiz, Diana Rosa
    Diaz Diaz, Jayce
    [J]. MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2015, 13 (04): : 478 - 480
  • [30] Use of Web technology for interactive remote instruction
    Maly, K
    Overstreet, CM
    Gonzales, A
    Denbar, M
    Cutaran, R
    Karunaratne, N
    Srinivas, CJ
    [J]. COMPUTER NETWORKS AND ISDN SYSTEMS, 1998, 30 (1-7): : 660 - 662